Richard Christopher net worth and biography

Richard Christopher Biography and Net Worth

CEO of Lexaria Bioscience

Mr. Christopher was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a company with a focus on therapies and solutions for the early identification and treatment of cancer, where he held both financial and operational responsibilities. Before joining iCAD, Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Preceding Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a dermatology company focused on the treatment of precancerous skin lesions. He was with DUSA for a period of 12.5 years, where he ultimately served as Chief Financial Officer for 8.5 years before the company’s acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.

What is Richard Christopher's net worth?: The estimated net worth of Richard Christopher is at least $14.99 thousand as of July 29th, 2025. Mr. Christopher owns 4,333 shares of Lexaria Bioscience stock worth more than $14,992 as of October 8th. This net worth approximation does not reflect any other assets that Mr. Christopher may own. Learn More about Richard Christopher's net worth.
How do I contact Richard Christopher?: The corporate mailing address for Mr. Christopher and other Lexaria Bioscience executives is 100 – 740 McCurdy Road, Kelowna, BC, V1X 2P7. Lexaria Bioscience can also be reached via phone at (250) 765-6424 and via email at [email protected]. Learn More on Richard Christopher's contact information.
Has Richard Christopher been buying or selling shares of Lexaria Bioscience?: Richard Christopher has not been actively trading shares of Lexaria Bioscience within the last three months. Most recently, on Tuesday, July 29th, Richard Christopher bought 1,000 shares of Lexaria Bioscience stock. The stock was acquired at an average cost of $13.65 per share, with a total value of $13,650.00. Following the completion of the transaction, the chief executive officer now directly owns 4,333 shares of the company's stock, valued at $59,145.45. Learn More on Richard Christopher's trading history.
Who are Lexaria Bioscience's active insiders?: Lexaria Bioscience's insider roster includes Christopher Bunka (Director), Richard Christopher (CEO), and John Docherty (Insider). Learn More on Lexaria Bioscience's active insiders.

Richard Christopher Insider Trading History at Lexaria Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/29/2025	Buy	1,000	$13.65	$13,650.00	4,333
12/2/2024	Buy	1,521	$33.60	$51,105.60	1,521

Richard Christopher Buying and Selling Activity at Lexaria Bioscience

Lexaria Bioscience Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Today's Range

Now: $3.37

$3.32

$3.67

50 Day Range

MA: $6.86

$2.77

$14.15

2 Week Range

Now: $3.37

$2.77

$21.60

Volume

10,378 shs

Average Volume

27,782 shs

Market Capitalization

$7.10 million

P/E Ratio

N/A

Dividend Yield